Search Results
Search for other papers by R Paul Robertson in
Google Scholar
PubMed
Introduction The editors asked that I write a brief introductory article for this special collection, which focuses on scientific advances in glucagon research and its clinical impacts. In doing so, I will provide a short history of glucagon
Search for other papers by Jennifer H Stern in
Google Scholar
PubMed
Search for other papers by Gordon I Smith in
Google Scholar
PubMed
Search for other papers by Shiuwei Chen in
Google Scholar
PubMed
Search for other papers by Roger H Unger in
Google Scholar
PubMed
Search for other papers by Samuel Klein in
Google Scholar
PubMed
Search for other papers by Philipp E Scherer in
Google Scholar
PubMed
a major focus of metabolic research in obesity, glucagon is also an important regulator of glycemic control. In fact, Orci and Unger’s ‘bihormonal hypothesis’ (1975) ( Unger & Orci 1975 ) prompted decades of work that created abundant evidence
Search for other papers by Wanbao Yang in
Google Scholar
PubMed
Search for other papers by Hui Yan in
Google Scholar
PubMed
Search for other papers by Quan Pan in
Google Scholar
PubMed
Search for other papers by James Zheng Shen in
Google Scholar
PubMed
Search for other papers by Fenghua Zhou in
Google Scholar
PubMed
Search for other papers by Chaodong Wu in
Google Scholar
PubMed
Search for other papers by Yuxiang Sun in
Google Scholar
PubMed
Search for other papers by Shaodong Guo in
Google Scholar
PubMed
Introduction Glucagon secreted from the α-cells of pancreatic islets is a predominant counter regulatory hormone to the action of insulin in control of blood glucose homeostasis ( Habegger et al. 2010 ). This 29 animo acid peptide hormone is
Search for other papers by Jasleen Kaur in
Google Scholar
PubMed
Search for other papers by Elizabeth R Seaquist in
Google Scholar
PubMed
Introduction Glucagon is a 29 amino acid pancreatic peptide hormone secreted by the pancreatic alpha cells. It is derived from the precursor hormone proglucagon, which is also a precursor for glucagon-like gut peptides ( Sandoval & D
Search for other papers by Rui Gao in
Google Scholar
PubMed
Department of Physiology, Institute of Neuroscience and Physiology, Metabolic Research Unit, University of Gothenburg, Göteborg, Sweden
Search for other papers by Samuel Acreman in
Google Scholar
PubMed
Search for other papers by Jinfang Ma in
Google Scholar
PubMed
Search for other papers by Fernando Abdulkader in
Google Scholar
PubMed
Search for other papers by Anna Wendt in
Google Scholar
PubMed
CNC - Center for Neuroscience and Cell Biology, CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
Search for other papers by Quan Zhang in
Google Scholar
PubMed
Introduction In the body, blood glucose levels are kept within a narrow range by concerted action of glucagon and insulin, the glucose-regulating hormones secreted by α- and β-cells, respectively ( Göke 2008 ). Whereas the islet α-cells were
Search for other papers by James Cantley in
Google Scholar
PubMed
Department of Medicine, Université de Montréal, Montréal, QC, Canada
Search for other papers by Vincent Poitout in
Google Scholar
PubMed
Department of Medicine, University of Washington, Seattle, Washington, USA
Search for other papers by Rebecca L Hull-Meichle in
Google Scholar
PubMed
Glucagon, the principal hormone produced by pancreatic islet alpha (α) cells, has a range of profound effects on metabolism including, but not limited to, stimulation of hepatic glucose production. Accordingly, glucagon has been utilised as a
Obesity Center, Faculty of Medicine, Biomedical Imaging and Life Sciences (IBILI), Department of Surgery A, Faculty of Medicine, Hospital de Santiago, EN 10, km 37, 2900‐722 Setubal, Portugal
Search for other papers by Hans Eickhoff in
Google Scholar
PubMed
Obesity Center, Faculty of Medicine, Biomedical Imaging and Life Sciences (IBILI), Department of Surgery A, Faculty of Medicine, Hospital de Santiago, EN 10, km 37, 2900‐722 Setubal, Portugal
Search for other papers by Teresa Louro in
Google Scholar
PubMed
Obesity Center, Faculty of Medicine, Biomedical Imaging and Life Sciences (IBILI), Department of Surgery A, Faculty of Medicine, Hospital de Santiago, EN 10, km 37, 2900‐722 Setubal, Portugal
Search for other papers by Paulo Matafome in
Google Scholar
PubMed
Obesity Center, Faculty of Medicine, Biomedical Imaging and Life Sciences (IBILI), Department of Surgery A, Faculty of Medicine, Hospital de Santiago, EN 10, km 37, 2900‐722 Setubal, Portugal
Search for other papers by Raquel Seiça in
Google Scholar
PubMed
Obesity Center, Faculty of Medicine, Biomedical Imaging and Life Sciences (IBILI), Department of Surgery A, Faculty of Medicine, Hospital de Santiago, EN 10, km 37, 2900‐722 Setubal, Portugal
Search for other papers by Francisco Castro e Sousa in
Google Scholar
PubMed
-dependent insulinotropic peptide (GIP) and reduced glucagon-like peptide 1 (GLP1) secretion seem to play an additional role in the development of type 2 diabetes ( Holst et al . 2009 ). Excessive or inadequate glucagon secretion promoting hepatic gluconeogenesis and
Search for other papers by Emma Rose McGlone in
Google Scholar
PubMed
Search for other papers by Stephen R Bloom in
Google Scholar
PubMed
Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed
Introduction Glucagon is a peptide hormone secreted by alpha cells in the pancreas which acts on several organs including the liver, kidney, heart and brain ( Marroqui et al. 2014 , Wewer Albrechtsen et al. 2023 ). The precursor protein
Search for other papers by Mingyu Li in
Google Scholar
PubMed
Search for other papers by E Danielle Dean in
Google Scholar
PubMed
Departments of Molecular Physiology and Biophysics, Division of Diabetes, Third Institute of Oceanography, Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt University School of Medicine, Light Hall, Room 711, 2215 Garland Avenue, Nashville, Tennessee 37232, USA
Search for other papers by Liyuan Zhao in
Google Scholar
PubMed
Search for other papers by Wendell E Nicholson in
Google Scholar
PubMed
Departments of Molecular Physiology and Biophysics, Division of Diabetes, Third Institute of Oceanography, Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt University School of Medicine, Light Hall, Room 711, 2215 Garland Avenue, Nashville, Tennessee 37232, USA
Departments of Molecular Physiology and Biophysics, Division of Diabetes, Third Institute of Oceanography, Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt University School of Medicine, Light Hall, Room 711, 2215 Garland Avenue, Nashville, Tennessee 37232, USA
Search for other papers by Alvin C Powers in
Google Scholar
PubMed
Search for other papers by Wenbiao Chen in
Google Scholar
PubMed
Introduction Glucagon is a peptide hormone secreted by pancreatic α-cells. It is the main counter-regulatory hormone of insulin. Glucagon acts primarily on liver through glucagon receptor (GCGR) to regulate hepatic glucose production ( Mayo et al
VCA Colonial Animal Hospital, Ithaca, New York, USA
Search for other papers by Michael Merkhassine in
Google Scholar
PubMed
Weill Cornell College of Medicine, New York, New York, USA
Search for other papers by Reilly W Coch in
Google Scholar
PubMed
Search for other papers by Carol E Frederick in
Google Scholar
PubMed
Search for other papers by Lucinda L Bennett in
Google Scholar
PubMed
Fate Therapeutics, San Diego, California, USA
Search for other papers by Seth A Peng in
Google Scholar
PubMed
Search for other papers by Benjamin Morse in
Google Scholar
PubMed
Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, California, USA
Search for other papers by Bethany P Cummings in
Google Scholar
PubMed
Search for other papers by John P Loftus in
Google Scholar
PubMed
Introduction Glucagon is a pancreatic endocrine hormone involved in regulating circulating glucose and amino acid (AA) levels and is an important therapeutic target for various metabolic and gastrointestinal conditions ( Unger & Cherrington